Results reveal mechanism of action and correlation analysis data
HELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) — TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, has announced its announced promising preliminary safety and efficacy data from a Phase I clinical trial (NCT05271318). Patients with refractory ovarian cancer at the American Association for Cancer Research (AACR) 2024 Annual Meeting.
TILT-123 in combination with MSD (trade name of Merck & Co., Inc., Rahway, New Jersey, USA) anti-PD-1 therapy Keytruda® (pembrolizumab) is safe and demonstrated signs of efficacy in both platinum-resistant and refractory ovarian cancer patients. Analysis of biological samples has revealed insights into mechanisms of action, including immunological profiles that may predict clinical response.
Study results showed that 15 patients received intratumoral or intraperitoneal administration of TILT-123 therapy in combination with intravenous pembrolizumab in an open-label phase I clinical trial using a standard 3+3 dose escalation scheme. of patients.
Of note, disease control was seen in 71% of evaluable patients, including one long-lasting partial response in a patient with mucinous carcinoma. Reductions in tumor size and significant immunomodulation were seen in injected and uninjected tumors, indicating the possibility of a systemic response.
The results demonstrated that a strong humoral response and increased presence of IgE+ plasma cells significantly correlated with clinical response and overall survival. They also revealed insights into the mechanism of action of combination therapy.
Akseli Heminki, founder and CEO of TILT Biotherapeutics and a cancer clinician who has personally treated hundreds of cancer patients infected with oncolytic viruses, said: He said so. “We are excited to confirm this latest and continuing positive possibility to bring more effective treatment to patients with refractory ovarian cancer who have few other treatment options. Importantly, intratumoral injection of combination therapy “Not only that, but we also observed an immune response and reduction in tumor size even when injected far from the tumor site, indicating the possibility of a systemic response.”
TILT-123 is an oncolytic adenovirus with tumor necrosis factor alpha (TNFα) and interleukin 2 (IL-2) that can be used for T-cell therapy, including adoptive cell transfer for immune checkpoint inhibition and reactivation. designed to increase the effectiveness of of the tumor microenvironment. TILT's approach uses oncolytic viruses to selectively replicate within cancer cells, lysing them while simultaneously stimulating an immune response against the tumor.
The results presented at AACR 2024, along with data from other ongoing trials, highlight the promise of TILT-123 as a novel cancer treatment. Continued clinical evaluation, including ongoing trials (NCT04695327, NCT04217473, NCT06125197, NCT05222932), will further elucidate the therapeutic potential of TILT-123 for various types of solid tumors.
reference:
Immune activation of oncolytic adenovirus encoding TNFα and IL-2 (TILT-123) in combination with pembrolizumab in patients with platinum-resistant or refractory ovarian cancer
keytruda® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA.
Note to editor
About TILT Biotherapeutics
TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer treatments based on proprietary oncolytic adenoviruses with molecules such as cytokines that can activate T cells to destroy cancer cells.
The company's patented TILT® This technique can be delivered intravenously, locally regionally, or intratumorally. It alters the tumor microenvironment and has broader systemic effects. By heating up cold tumors, we eliminate the cancer's ability to evade the immune response, thereby enhancing T-cell therapies such as immune checkpoint inhibitors, tumor-infiltrating lymphocyte (TIL) therapy, and CAR T therapy. .
TILT's main asset, TILT-123, is also known as Iglelimogene Ritadenorebbekis a 5/3 chimeric serotype adenovirus with two human cytokines, TNF α and IL-2. Approximately 50 patients were treated in four international trials sponsored by the company, and promising initial efficacy responses were observed in some patients.
The company's pioneering approach is recognized by industry leaders. The company has twice partnered with MSD, a trade name for Merck & Co., to study TILT-123 in combination with Keytruda.® (pembrolizumab) in ovarian cancer (NCT05271318) and refractory non-small cell lung cancer (NCT06125197). The company is also collaborating with Merck KGaA in Darmstadt, Germany, to study the combination of TILT-123 and avelumab.
Headquartered in Helsinki, Finland, with additional offices in Boston, the company was founded more than a decade ago as a spinout from the University of Helsinki. Funded by Lifeline Ventures, Finnish Industry Investment (TESI), angel investors, Business Finland, the European Innovation Council, and the US Department of Defense.
media contact
TILT Biopharmaceuticals
COO Aino Kalerbo
aino@tiltbio.com
Schaus Communications
Katya Stout
+447789435990
katja@sciuscommunications.com
daniel gooch
+447747875479
daniel@sciuscommunications.com